Loading data
IBONYSE
| Unit: USD | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 32 k USD | — | — | 50 k USD | — |
| Cost of revenue | 424 k USD | — | — | — | — |
| Research and development expense | 340 k USD | 278 k USD | 1.69 m USD | 1.23 m USD | 1.08 m USD |
| Selling, general and administrative expense | 873 k USD | 718 k USD | 315 k USD | 325 k USD | 398 k USD |
| Operating profit | -4.28 m USD | -28.75 m USD | -4.03 m USD | -3.4 m USD | -3.19 m USD |
| Interest expense | 793 k USD | 1.07 m USD | 444 k USD | 462 k USD | 300 k USD |
| Profit before tax | -14.45 m USD | -24.74 m USD | -4.41 m USD | -7.88 m USD | -3.24 m USD |
| Income tax expense | -2.58 m USD | 33 k USD | — | -621 k USD | -1.4 m USD |
| Net income (reported basis) | -11.84 m USD | -24.71 m USD | -4.34 m USD | -7.26 m USD | -1.3 m USD |
| Net income attributable to common shareholders | — | — | -4.34 m USD | -7.05 m USD | — |
| Basic earnings per share | -0.38 USD/share | -2.3 USD/share | -0.07 USD/share | -0.1 USD/share | 0 USD/share |
| Diluted earnings per share | -0.38 USD/share | -2.3 USD/share | -0.07 USD/share | -0.1 USD/share | — |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.